Also known as: Litfulo
FDA-approved oral JAK3/TEC inhibitor for alopecia areata in patients 12 and older.
Ritlecitinib irreversibly inhibits JAK3 and the TEC family of kinases. JAK3 inhibition blocks IL-15 and IL-21 signaling critical for cytotoxic CD8+ T cell activation that attacks hair follicles in alopecia areata. TEC kinase inhibition provides additional suppression of T cell and NK cell responses.
Unlock Premium Content
Get full access to in-depth analyses, cited studies, premium articles, and AI chat.
$12/mo
View pricing